

ISSUE @ A GLANCE

The growing spectrum of cardiomyopathies: risk assessment and management

T.F. Lüscher

945

CardioPulse

Plan S: in service or disservice to society?

T.J. Guzik and A. Ahluwalia

949

The cOALition S and Plan S: explained

A. Tofield

952

Exosomes for cardioprotection: are we ready for clinical translation?

T.Z. Nazari-Shafti, C. Stamm, V. Falk, and M.Y. Emmert

953

The Liverpool Centre for Cardiovascular Science

G.Y.H. Lip and D.A. Lane

957

Ellen Hoffman, new EHJ International Editorial Board Member

959

CLINICAL REVIEW

Myocardial disease

Can we remove scar and fibrosis from adult human myocardium?

A. Vazir, K. Fox, J. Westaby, M.J. Evans, and S. Westaby

960

BASIC SCIENCE

Myocardial disease

Deletion of delta-like 1 homologue accelerates fibroblast-myofibroblast differentiation and induces myocardial fibrosis

P. Rodriguez, Y. Sassi, L. Troncone, L. Benard, K. Ishikawa, R.E. Gordon, S. Lamas, J. Laborda, R.J. Hajjar, and D. Lebecque

967

Editorial

Myocardial fibrosis as a matter of cell differentiation: opportunities for new antifibrotic strategies

C. Tschope and J. Díez

979

CURRENT OPINION

Sports cardiology


The electrocardiogram and the phenotypic expression of hypertrophic cardiomyopathy

S. Caselli and A. Pelliccia

982

CLINICAL RESEARCH

Myocardial disease



Clinical presentation and survival of childhood hypertrophic cardiomyopathy: a retrospective study in United Kingdom

G. Norrish, E. Field, K. Mcleod, M. Ilina, G. Stuart, V. Bhole, O. Uzun, E. Brown, P.E.F. Daubeney, A. Lota, K. Linter, S. Mathur, T. Bharucha, K.L. Kok, S. Adwani, C.B. Jones, Z. Reinhardt, and J.P. Kaski

986

Editorial**The hypertrophic cardiomyopathy paradox: better with age**

J.B. Geske and B.J. Gersh

994

BASIC SCIENCE**Obesity and metabolic syndrome****Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy**

S. Costantino, A. Akhmedov, G. Melina, S.A. Mohammed, A. Othman, S. Ambrosini, W.J. Wijnen, L. Sada, G.M. Ciavarella, L. Liberale, F.C. Tanner, C.M. Matter, T. Hornemann, M. Volpe, F. Mechta-Grigoriou, G.G. Camici, R. Sinatra, T.F. Lüscher, and F. Paneni

997

VIEWPOINT**Heart failure cardiomyopathy****Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?**

R.H. Falk

1009

DISCUSSION FORUM**Macrophage: beyond cardiac structural remodelling**

T. Xiong, X.-Q. Yang, and D.-X. Wang

1013

Is steroid therapy really banned for lymphocytic myocarditis before excluding viral infection?

T. Saito, H. Katayama, and E. Kodani

1014

CARDIOVASCULAR FLASHLIGHTS**Endomyocardial fibrosis presenting as apical calcification and infective endocarditis**

T. Aikawa, K. Kamiya, T. Mitsuhashi, and T. Anzai

1016

An unusual case of cardiac aspergillosis

A.F. Cereda, L. Fiocca, L. Cattaneo, A. Iacovoni, S. Sironi and M. Senni

1017

LIST OF REVIEWERS**List of Reviewers 2018**

1018

**Open Access Paper****For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>**

Visit EHJ's mobile site
<https://academic.oup.com/eurheartj>

www.eurheartj.org